Novo Nordisk A/S Target of Unusually High Options Trading (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) was the recipient of some unusual options trading on Tuesday. Investors bought 137,025 call options on the company. This represents an increase of approximately 44% compared to the typical daily volume of 95,143 call options.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of institutional investors have recently added to or reduced their stakes in the company. True Wealth Design LLC lifted its holdings in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after buying an additional 300 shares in the last quarter. Guerra Advisors Inc purchased a new stake in shares of Novo Nordisk A/S during the third quarter worth about $25,000. Strengthening Families & Communities LLC acquired a new position in shares of Novo Nordisk A/S in the third quarter worth about $30,000. NewSquare Capital LLC lifted its stake in shares of Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after acquiring an additional 282 shares in the last quarter. Finally, Allianz SE lifted its stake in shares of Novo Nordisk A/S by 70.0% in the third quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after acquiring an additional 238 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the topic of several recent research reports. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Jefferies Financial Group began coverage on shares of Novo Nordisk A/S in a report on Monday, October 27th. They set an “underperform” rating for the company. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $53.33.

Novo Nordisk A/S Price Performance

NVO opened at $52.61 on Thursday. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The company’s 50 day simple moving average is $49.47 and its 200 day simple moving average is $57.12. The stock has a market capitalization of $234.90 billion, a PE ratio of 15.29 and a beta of 0.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approval of the oral Wegovy pill gives Novo a first‑to‑market position in oral GLP‑1 obesity treatments, expanding addressable market and making the drug easier to prescribe/scale than injectables. Explainer: What Novo Nordisk’s weight-loss pill approval means
• Positive Sentiment: Novo plans a U.S. launch in early January and is targeting the cash‑pay market at an introductory price (~$149/month reported), which could accelerate uptake and revenue if demand matches expectations. Wegovy pill to test demand from consumers with cash
• Positive Sentiment: Market reaction: multiple outlets report a sharp pre‑market/early session rally and unusually large call‑option activity, signaling investor optimism and short‑term speculative interest. Shares pop after GLP-1 pill approval
• Neutral Sentiment: Analysts highlight that NVO trades at a depressed forward multiple (seekingalpha note), so the approval could meaningfully re‑rate the stock if commercial execution succeeds — but valuation upside depends on sustained share gains. Seeking Alpha: The real comeback starts now with the Wegovy pill
• Negative Sentiment: Competition and pricing pressure remain material risks — Eli Lilly is close behind with its own oral option and dominates prescriptions with injectables, so market share battles and price competition could limit upside. Lilly, Novo lock horns in India’s obesity drug race
• Negative Sentiment: Geographic/generic risks—lower‑cost generics and delayed filings in some markets (e.g., Canada/India) could pressure future volumes and margins in regional markets. Canadians face longer wait for copycat Ozempic

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.